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Most current articleIn patientswith nonalcoholic fatty liverdisease (NAFLD), nonalcoholic steatohepatitis (NASH) is a
risk factor for the development of ﬁbrosis. However, ﬁbrosis has been observed in livers of pa-
tients without NASH. We aimed to estimate the prevalence of ﬁbrosis in patients without NASH
and risk factors for ﬁbrosis.METHODS: Weanalyzeddata from1738 subjects (44.9%with severeobesity) in a cross-sectional liver biopsy
cohort enrolled at referral centers in Italy and Finland. Biopsy specimens were analyzed histo-
logically by a blinded pathologist at each center, and a diagnosis of NASH was made based on
steatosis (‡5% of hepatocytes), hepatocellular ballooning, and lobular inﬂammation. We also
collected data on demographic features, metabolic comorbidities, and genetic factors, and per-
formed logistic regression analyses. Findings were validated using data from 118 consecutive
patients with NAFLDwho underwent sequential liver biopsies at tertiary referral centers in Italy.RESULTS: In the cross-sectional cohort, 132 of 389 patients (33.9%) with signiﬁcant ﬁbrosis had no NASH
and 39 patients (10.0%) had no inﬂammation. The dissociation between NASH and ﬁbrosis was
signiﬁcantly greater in patients with severe obesity (P < .005). Steatosis, ballooning, and lobular
inﬂammation each were associated independently with signiﬁcant ﬁbrosis (P < .001); age,
adiposity, fasting hyperglycemia, and the PNPLA3 I148M variant also were associated with
ﬁbrosis. In patients without, but not in those with NASH, signiﬁcant ﬁbrosis was associated with
steatosis grade and the PNPLA3 I148M variant. In patients without NASH, age, fasting hyper-
glycemia, ballooning, and inﬂammation were associated with ﬁbrosis. In the validation cohort,
16 of 47 patients (34.0%) with clinically signiﬁcant ﬁbrosis did not have NASH at baseline. In
patients with ﬁbrosis without baseline NASH, worsening of ﬁbrosis (based on later biopsies)
was associated with fasting hyperglycemia and more severe steatosis (P [ .016).er: BMI, body mass index; SF, clinically
is progression rate; NAFLD, nonalcoholic
nalcoholic steatohepatitis; T2D, type 2
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October 2019 Fibrosis in Fatty Liver Without NASH 2311CONCLUSIONS: In an analysis of biopsy specimens collected from patients with NAFLD at a single time point, one
third of patients with signiﬁcant ﬁbrosis did not have NASH. We validated this ﬁnding in a
separate cohort. In patients without NASH, fasting hyperglycemia, severe steatosis, mild inﬂam-
mation or ballooning, and thePNPLA3 I148Mvariant identiﬁed those at riskof signiﬁcantﬁbrosis.Keywords: History; Progression; Risk Factors; Inﬂammatory Response.What You Need to Know
Background
Nonalcoholic steatohepatitis (NASH) is the major risk
factor for signiﬁcant ﬁbrosis in patients with nonal-
coholic fatty liver disease (NAFLD). It is not clear
how many patients with NAFLD develop signiﬁcant
ﬁbrosis without NASH, or what the risk factors for
ﬁbrosis are in this subgroup.
Findings
Signiﬁcant ﬁbrosis was observed in approximately
one third of patients with NAFLD in the absence of
NASH. In these individuals, fasting hyperglycemia,
severe steatosis, mild inﬂammation/ballooning, and
the PNPLA3 I148M variant identiﬁed those at higher
risk of signiﬁcant ﬁbrosis.
Implications for patient care
The severity of hepatic fat accumulation and the
presence of the PNPLA3 I148M variant can identify
patients at risk of signiﬁcant ﬁbrosis even in the
absence of NASH.Nonalcoholic fatty liver disease (NAFLD), deﬁned inthe presence of increased hepatic fat content not
explained by at-risk alcohol intake, has become the leading
cause of liver disease.1 NAFLD is associatedwith excessive
adiposity, insulin resistance, physical inactivity, and qual-
itative alterations of the diet and microbiota.2 The factors
that drive disease progression are heterogeneous, encom-
passing multiple hits leading to inﬂammation and the
development of nonalcoholic steatohepatitis (NASH),3
with genetic factors playing an important role.4
NASH is characterized by fatty liver, associated with
both hepatocellular damage and lobular inﬂammation.5
NASH has been linked with a faster progression of
liver ﬁbrosis,6 and lobular inﬂammation may be a
marker of more severe disease even in patients without
NASH.7 However, ﬁbrosis frequently progresses even in
patients without baseline NASH.6,8,9 In selected cohorts
of patients with aggressive disease, ballooning and
lobular inﬂammation predicted ﬁbrosis progression.10,11
On the other hand, hepatic fat has also been linked with
liver ﬁbrosis progression,12,13 in line with genetic evi-
dence that hepatic lipid accumulation drives secondary
inﬂammation and ﬁbrogenesis.14
Although progressive NAFLD appears to be a het-
erogeneous disease, with variable involvement of genetic
defects4 and metabolic factors15 in triggering ﬁbro-
genesis independently of inﬂammation, therapeutic
studies presently are focused on the resolution of NASH
in patients with severe histologic activity.16 However, the
burden of NAFLD that progresses to clinically signiﬁcant
ﬁbrosis (SF) in the absence of NASH, and the risk factors
of clinically SF in these patients are not known. The an-
swers to these questions have implications for modeling
of disease burden,17 for the design of therapeutic trials,
and for the applicability of results to clinical practice.
The aim of this study was to examine the prevalence
of NAFLD with SF not associated with NASH and/or
inﬂammation in a large multicenter cohort and to iden-
tify the risk factors for SF in this subgroup. We validated
our ﬁndings from our multi-center cohort in a separate
prospective cohort.Patients and Methods
Study Cohorts
Part of the cross-sectional liver biopsy cohort has been
described previously.18 Brieﬂy, a total of 1738 individuals
of European descent were consecutively enrolled fromItalian and Finnish referral centers. Inclusion criteriawere
liver biopsy for suspected NASH (steatosis with increased
liver enzyme levels, severe insulin resistance, or other risk
factors for NASH) or severe obesity (body mass index
[BMI]> 40 kg/m2), presence of NAFLD, and availability of
clinical data and consent. Individuals with increased
alcohol intake (men,>30 g/d; women,>20 g/d), viral and
autoimmune hepatitis, or other causes of liver disease
were excluded. The study conformed to the Declaration of
Helsinki and was approved by the Institutional Review
Board of the Fondazione Ca’ Granda Istituto di Ricovero e
Cura a Carattere Scientiﬁco (IRCCS) of Milan. The clinical
features of the overall cross-sectional liver biopsy cohort
and are presented in Supplementary Table 1.
To validate the results prospectively, we took
advantage of a previously described multicenter cohort
of 118 patients with NAFLD with serial liver biopsies
followed at tertiary referral centers in Italy.9 The clinical
features are described in the Supplementary Methods
section.
Histologic Evaluation
Slides were coded and read by 1 expert pathologist at
each center who was unaware of patients’ identity and
Figure 1. (A) Prevalence of nonalcoholic steatohepatitis (NASH) and lobular inﬂammation not fulﬁlling NASH criteria, vs simple
steatosis according to ﬁbrosis stage in the overall cohort (n ¼ 1738), and in patients stratiﬁed by recruitment criterion (referral
for liver disease or for severe obesity). (B) The same analysis was conducted in patients stratiﬁed by the presence of fasting
hyperglycemia. T2D, type 2 diabetes; IFG, impaired fasting glucose.
2312 Pelusi et al Clinical Gastroenterology and Hepatology Vol. 17, No. 11history. Disease activity was assessed according to the
NAFLD Activity Score; ﬁbrosis also was staged according
to the recommendations of the NAFLD clinical research
network.5 NASH was diagnosed when steatosis (5% of
hepatocytes), hepatocellular ballooning, and lobular
inﬂammation all were present, irrespective of ﬁbrosis. SF
was deﬁned when ﬁbrosis stage was 1 or higher. The
concordance between pathologists within this cohort (1
expert pathologist for each center) was very good for
ﬁbrosis, and good for steatosis with a coefﬁcient of
interobserver agreement for ﬁbrosis, steatosis grade,
lobular inﬂammation, and ballooning of 0.89, 0.76, 0.60,
and 0.55, respectively.19Genotyping
When DNA samples and consent were available,
the study cohorts were genotyped for rs738409 C>G
(PNPLA3 I148M) by TaqMan 5’-nuclease assays
(Life Technologies, Carlsbad, CA), as previously
described.9,18Statistical Analysis
Analyses were performed using generalized linear
models: linear regression models were ﬁt to analyze
Figure 2. Frequency distribution of the severity of steatosis, ballooning, and lobular inﬂammation according to the diagnosis of
nonalcoholic steatohepatitis (NASH), steatosis plus inﬂammation, and simple steatosis in the overall cohort and in patients
stratiﬁed according to the presence of clinically signiﬁcant ﬁbrosis.
October 2019 Fibrosis in Fatty Liver Without NASH 2313continuous traits (ﬁbrosis progression rate [FPR]), and
logistic regression for binary traits (SF). Models were
adjusted for confounding factors, as speciﬁed. For the
evaluation of risk factors of ﬁbrosis, we focused on de-
mographic features (age, sex), speciﬁc histologic features of
NAFLD (steatosis, ballooning, lobular inﬂammation),
metabolic comorbidities (BMI and impaired fasting
glucose/type 2 diabetes [T2D]), which were available in
all patients, and genetic factors (PNPLA3 I148M variant,
tested assuming an additive model), available in 1698
patients in the cross-sectional cohort (97.7% of the whole
cohort), to assess the factors potentially determining
ﬁbrosis development. Participants with missing genetic
data were dropped from the ﬁnal multivariate models.
In the prospective cohort, the I148M variant was not
considered because it was not available in the majority
of patients. Variables with skewed distributions were
transformed logarithmically before entering the models.
The interaction between NASH and confounding variables
in determining the risk of SF was formally tested
by entering the product term in the ﬁnal multivariate
models.
Statistical analyses were performed using JMP 12.0
(SAS Institute, Cary, NC) and R statistical analysis
software version 3.3.2 (http://www.R-project.org). P
values less than .05 were considered statistically
signiﬁcant.Results
Impact of Nonalcoholic Steatohepatitis and
Inﬂammation on Fibrosis in the Cross-Sectional
Cohort
Of the overall cohort, 32.9% of patients had NASH
and 22.4% had SF. The SF prevalence in patients with
and without NASH was 257 of 571 (45.0%) vs 132 of
1165 (11.3%), respectively (P ¼ 2*10-53). The histologic
activity in patients stratiﬁed by ﬁbrosis stage is shown in
Supplementary Table 2. The frequency of NASH, steatosis
associated with inﬂammation, and simple steatosis ac-
cording to ﬁbrosis stage is shown in Figure 1A (left
panel). Expectedly, there was a trend for an increasing
prevalence of NASH with worsening of ﬁbrosis (P ¼
4*10-83). Most patients without ﬁbrosis had simple
steatosis. However, as many as 132 of 389 (33.9%) pa-
tients with SF had no NASH, and 39 of 389 (10%) pa-
tients with SF had no lobular inﬂammation.
The proportion of patients with SF despite the
absence of lobular inﬂammation at the time of biopsy
was higher in severely obese individuals (P ¼ .0002)
(Figure 1A, right panel). NASH was more prevalent in
patients with fasting hyperglycemia than in those with
normal glucose tolerance, and a lack of inﬂammation was
Table 1. Clinical Features of the Study Cohorts Stratiﬁed by the Presence of NASH, Steatosis Associated With Lobular
Inﬂammation, or Simple Steatosis
NASH
Steatosis plus
inﬂammation
Simple
steatosis
P
value
Cross-sectional LBC cohort
N 571 (32.8) 465 (26.8) 702 (40.4)
Sex, female 230 (40.3) 197 (42.4) 433 (61.7) <.0001
Age, y 44.7  17.0 40.8  16.8 44.7  10.7 <.0001
BMI, kg/m2 32.2  7.7 33.5  9.2 37.3  9.0 <.0001
Obesity 292 (51.1) 247 (53.1) 508 (72.4) <.0001
T2D/IFG, yes 211 (37.0) 119 (25.6) 136 (19.4) <.0001
Hypertension, yes 166 (34.2) 123 (30.1) 159 (35.4) .23
Total cholesterol, mg/dL 191  45 196  45 187  43 .0036
Triglyceride level, mg/dL 147  77 140  79 131  74 .0017
HDL cholesterol, mg/dL 47  14 48  14 48  14 .65
ALT level, IU/L 59 (38–88) 48 (26–76) 30 (19–45) <.0001
AST level, IU/L 39 (28–54) 30 (21–46) 22 (17–31) <.0001
SF, yes 257 (45.0) 93 (20.0) 39 (5.6) <.0001
Severe ﬁbrosis,
stages F3–F4
139 (24.3) 20 (4.3) 15 (2.1) <.0001
PNPLA3, 148M/Ma 107 (19.0) 74 (16.2) 53 (7.8) <.0001
Prospective cohort
N 49 (41.5) 46 (39.0) 23 (19.5)
Sex, female 21 (42.9) 15 (32.6) 9 (39.1) .58
Age, y 47.9  13.2 46.4  12.0 47.5  12.5 .80
BMI, kg/m2 30.0  4.1 31.1  1.0 30.6  1.4 .72
Obesity 24 (49.0) 19 (41.3) 10 (43.5) .75
T2D/IFG, yes 28 (58.3) 14 (30.4) 4 (17.4) .001
Hypertension, yes 20 (40.8) 10 (21.7) 8 (34.8) .13
LDL cholesterol, mg/dL 115  36 125  43 133  33 .16
Triglyceride level, mg/dL 136  70 142  86 109  47 .21
HDL cholesterol, mg/dL 48  15 46  12 50  15 .50
ALT level, IU/L 57 (42–95) 51 (26–82) 35 (21–63) .78
AST level, IU/L 37 (27–62) 34 (22–40) 24 (19–39) .52
SF, yes 31 (63.3) 15 (32.6) 1 (4.4) <.0001
Severe ﬁbrosis,
stages F3–F4
19 (38.8) 8 (17.4) 0 <.0001
FPR, stages/y -0.011  0.055 þ0.005  0.040 þ0.002  0.011 .16
Fibrosis progression, yes 15 (30.6) 12 (26.1) 3 (13.0) .13
PNPLA3, 148M/Mb 12 (44.4) 11 (28.2) 2 (8.7) .0061
NOTE. Values are reported as means  SD, median {interquartile range}, or number (%), as appropriate. Characteristics of participants were compared using a
linear regression model or a logistic regression model (as required).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FPR, ﬁbrosis progression rate; HDL, high-density lipoprotein; IFG,
impaired fasting glucose; LBC, liver biopsy cohort; LDL, low-density lipoprotein; NASH, nonalcoholic steatohepatitis; SF, clinically signiﬁcant ﬁbrosis; T2D, type 2
diabetes.
aThe PNPLA3 I148M genotype was available in a subset of 1698 patients.
bThe PNPLA3 I148M genotype was available in a subset of 89 patients.
2314 Pelusi et al Clinical Gastroenterology and Hepatology Vol. 17, No. 11observed in 4 of 24 (16.7%) cirrhotic patients with
normal glucose tolerance (Figure 1B). Despite the anal-
ysis being limited by the reduced sample size, there was
no association between NASH and ﬁbrosis in develop-
mental age patients (Supplementary Figure 1A), whereas
the association between NASH and ﬁbrosis was not
inﬂuenced signiﬁcantly by sex (Supplementary
Figure 1B), or by carriage of the PNPLA3 I148M variant
(Supplementary Figure 1C).
Histologic Predictors of Signiﬁcant Fibrosis in
the Cross-Sectional Cohort
Histologic features of NAFLD in patients in the cross-
sectional cohort stratiﬁed by the severity of liver damageare shown in Figure 2 (upper panel). NASH was char-
acterized by the presence of the most severe grade of
steatosis, ballooning, and lobular inﬂammation, whereas
steatosis plus inﬂammation had an intermediate stea-
tosis and inﬂammatory grade, and simple steatosis had
the lowest grade of steatosis and, by deﬁnition, no
inﬂammation.
The clinical features of patients stratiﬁed by the pres-
ence of NASH or of lobular inﬂammation are presented in
Table 1 (upper panel). Therewas a progressive increase in
the prevalence of impaired fasting glucose/T2D and
higher triglyceride levels with increasing disease activity
(from simple steatosis, to steatosis plus inﬂammation, and
next NASH), as well as a progressive increase in the fre-
quency of homozygosity of the PNPLA3 I148M variant.
Table 2. Independent Predictors of Clinically Signiﬁcant Fibrosis (Stages F2–F4) in the Overall Cross-Sectional LBC Cohort
and in Patients Stratiﬁed According to Modality of Enrollment (Liver Clinic Vs Severe Obesity)
Overall Liver clinic Severe obesity
Estimate SE
P
value Estimate SE
P
value Estimate SE
P
value
Sex, female 0.143 0.078 .061 þ0.014 0.009 .88 -0.400 0.106 .0018
Age, y þ0.037 0.005 7*10-14 þ0.040 0.005 7*10-13 þ0.014 0.011 .23
BMI, kg/m2 þ0.038 0.015 .009 þ0.054 0.023 .021 þ0.022 0.020 .24
T2D/IFG, yes þ0.480 0.079 1*10-9 þ0.503 0.098 8*10-8 þ0.350 0.129 .0067
Steatosis, grade þ0.399 0.079 3*10-7 þ0.338 0.098 6*10-4 þ0.547 0.139 9*10-5
Ballooning, grade þ0.608 0.103 4*10-9 þ0.571 0.113 5*10-7 þ0.776 0.266 .0036
Lobular inﬂammation, grade þ0.779 0.081 2*10-21 þ0.733 0.098 2*10-13 þ0.772 0.266 2*10-7
PNPLA3, I148M allelesa þ0.326 0.101 .0001 þ0.231 0.125 .064 þ0.550 0.183 .0036
NOTE. Characteristics of participants were compared using linear regression models. Results in the overall cohort were adjusted for enrollment criterion (liver clinic
vs severe obesity), and the covariates shown.
BMI, body mass index; IFG, impaired fasting glucose; LBC, liver biopsy cohort; T2D, type 2 diabetes.
aThe PNPLA3 I148M genotype was available in a subset of patients (n ¼ 1698).
October 2019 Fibrosis in Fatty Liver Without NASH 2315The independent predictors of SF are presented in
Table 2. SF was associated independently with each
feature of NAFLD activity (steatosis, hepatocellular
ballooning, and lobular inﬂammation) after adjustment
for confounders, both in the overall cohort and in the
subcohorts. Besides NASH features, fasting hyperglyce-
mia and the PNPLA3 I148M variant increased the risk,
the independent impact of the latter being larger in
severely obese patients. Furthermore, SF was associated
with older age and adiposity in the overall cohort and in
the liver clinic subgroup, but not in severely obese in-
dividuals. Conversely, female sex was protective in
severely obese individuals, although there was no dif-
ference in the mean age in females according to
recruitment criterion (44.5  19 y in severely obese vs
45.2  9.9 y in liver clinic patients; P ¼ .58).Predictors of Signiﬁcant Fibrosis According to
Nonalcoholic Steatohepatitis in the Cross-
Sectional Cohort
The frequency distribution of the histologic grade of
steatosis, hepatocellular ballooning, and lobular inﬂam-
mation between patients who had developed SF or not,
stratiﬁed by the presence of NASH, steatosis plus
inﬂammation, or simple steatosis, is shown in Figure 2
(bottom panel). In patients with NASH, steatosis grade
tended to be severe independently of ﬁbrosis. On the
other hand, steatosis was more severe in patients with
steatosis and inﬂammation and in those with steatosis
alone who developed SF. SF was associated with
ballooning in patients with NASH and simple steatosis,
and with more severe inﬂammation in those with NASH
and steatosis plus inﬂammation.
The independent predictors of SF in patients strati-
ﬁed by the presence of NASH are presented in Table 3. In
patients with NASH, SF was associated with more severeballooning and inﬂammation, and with older age and
fasting hyperglycemia. In patients without NASH, SF was
associated with more severe steatosis, inﬂammation, and
ﬁbrosis, and with older age, fasting hyperglycemia, and
the PNPLA3 I148M variant. Steatosis grade and the
PNPLA3 I148M variant seemed to have a relatively
greater effect on SF in patients not fulﬁlling NASH
criteria. Even at univariate analysis, the PNPLA3 I148M
variant had a larger effect size on SF in patients without
(estimate, þ0.552, 0.132; P ¼ 3*10-5), than in those with
NASH (estimate, þ0.239, 0.118; P ¼ .003). Results were
similar when patients were stratiﬁed further by the
presence of severe obesity (Supplementary Table 3).
In particular, steatosis grade and the PNPLA3 I148M
variant were associated independently with SF in pa-
tients without, but not in those with NASH in both
subcohorts.
When patients without NASH were stratiﬁed by the
presence of lobular inﬂammation, in those with inﬂam-
mation, SF was associated with steatosis and inﬂamma-
tory grade, and with older age, male sex, fasting
hyperglycemia, and the PNPLA3 I148M variant. In pa-
tients without inﬂammation, SF was associated with
more severe steatosis and ballooning, and with adiposity
and the PNPLA3 I148M variant.
Additional sensitivity analyses are provided in the
Supplementary Results section (see also Supplementary
Tables 4–6); results generally were consistent with
those observed in the whole cohort.Predictors of Fibrosis Evolution According to
Nonalcoholic Steatohepatitis in the Prospective
Cohort
The baseline clinical features of patients included in
the prospective cohort stratiﬁed by liver disease activity
are reshown in Table 1 (bottom panel). The independent
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patients stratiﬁed according to disease activity are
shown in Table 4. In the overall cohort, faster FPR was
associated with fasting hyperglycemia, but not with other
severe features of liver damage. After stratiﬁcation for
the presence of NASH, in patients with NASH, faster FPR
was associated with male sex and more severe
ballooning. In patients without NASH, faster FPR was
associated independently with fasting hyperglycemia
and steatosis grade.
In patients without baseline NASH who had ﬁbrosis
progression at follow-up evaluation, we observed a
higher rate of NASH diagnosis at follow-up evaluation as
compared with nonprogressors (6 of 15 [40.0%] vs 8 of
54 [14.8%]; P ¼ .043), whereas the variation in BMI,
liver enzyme levels, and T2D incidence were not signif-
icantly different (not shown).Discussion
In a large European multicenter cohort of patients
with NAFLD, we examined the prevalence and risk fac-
tors of SF in the absence of histologic NASH. We found
that the prevalence of SF in the absence of NASH was
much higher than that estimated by recent epidemiologic
studies. Furthermore, risk factors for SF were different in
patients with compared with patients without NASH, in
which a larger role was played by steatosis severity and
the PNPLA3 I148M variant.
More than one third of SF patients did not have NASH,
and more than 1 in 10 did not have any sign of histologic
inﬂammation. Although the association between NASH
and SF was inﬂuenced by severe obesity, in that in-
dividuals referred for this condition had a higher prev-
alence of SF in the absence of NASH, 27% of patients
referred to a liver clinic with SF did not have NASH, and
7% had no inﬂammation. Approximately 10% of patients
with cirrhosis had no signs of lobular inﬂammation,
possibly owing to burnt-out disease in a fraction of these
individuals.20 However, the prevalence of SF in the
absence of NASH was higher in patients with ﬁbrosis
stages 2 and 3 than in those with cirrhosis, and in
patients without NASH, SF was associated with more
severe steatosis, which would not be in line with burnt-
out disease. It is possible that these individuals were
experiencing a phase of temporary remission of disease
activity at the time of biopsy, leading to reduced
ballooning and inﬂammation, but without improvement
in ﬁbrosis. Notwithstanding, the prevalence of SF in
the absence of NASH in this study was several-fold
higher than that estimated in recent epidemiologic pro-
jections of the burden of NAFLD (approximately 5%),17
suggesting that the disease evolution may have been
underestimated.17
The higher prevalence of SF in the absence of NASH in
severely obese patients may be explained by the direct
impact of insulin resistance in disease progression
Table 4. Independent Predictors of Fibrosis Progression Rate in the Overall NAFLD Prospective Cohort (n ¼ 118) and Stratiﬁed
According to the Presence of NASH
Overall NASH No NASH
Estimate SE P value Estimate SE P value Estimate SE P value
Sex, female þ0.001 0.004 .74 0.014 0.007 .032 þ0.001 0.004 .30
Age, y þ0.001 0.001 .35 þ0.001 0.001 .31 þ0.001 0.001 .93
T2D/IFG, yes þ0.013 0.005 .014 þ0.009 0.009 .38 þ0.013 0.005 3.6*10-5
Steatosis, grade >1 þ0.014 0.010 .22 þ0.005 0.015 .89 þ0.021 0.010 .016
Ballooning, grade >0 -0.019 0.009 .047 þ0.036 0.014 .012 þ0.015 0.017 .36
Lobular inﬂammation,
grade >1
þ0.010 0.010 .55 þ0.024 0.016 .14 þ0.001 0.001 .66
NOTE. Characteristics of participants were compared using linear regression models. All results were adjusted for the covariates shown in the table, and for
baseline ﬁbrosis stage.
IFG, impaired fasting glucose; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; T2D, type 2 diabetes.
October 2019 Fibrosis in Fatty Liver Without NASH 2317independent of inﬂammation.15,21 Alternatively, the
more prolonged fasting advised before undergoing bar-
iatric surgery than before liver biopsy performed in
outpatients may have improved disease activity in
severely obese patients, partially masking the contribu-
tion of inﬂammation to SF development in this subgroup.
Indeed, little is known about the impact of the duration
of fasting as well as of the quality of diet in the period
immediately preceding evaluation of liver damage (either
by liver biopsy or by noninvasive approaches) on disease
activity. Such information would allow a better inter-
pretation of the results and standardization of the
procedures.
Second, we found that each of the individual major
features of NASH, namely steatosis, ballooning, and
lobular inﬂammation, was independently associated
with SF. These data suggest that they reﬂect different
pathophysiological aspects of the disease (eg, fat accu-
mulation, oxidative stress, and inﬂammation), which
contribute to disease pathogenesis.14 Furthermore, the
impact of fasting hyperglycemia and severe insulin
resistance was independent of the histologic activity of
the disease,15,22 suggesting that it may be mediated
directly by glucose toxicity or alteration in insulin
signaling pathways.15,21,23 In addition, it is worth
noting that the PNPLA3 I148M variant was associated
with SF independently of the well-established impact
on histologic fat and inﬂammation, in keeping with a
further direct effect of this mutation on ﬁbrogenesis by
acting on retinol/lipid metabolism in hepatic stellate
cells.24–27
Importantly, the risk factors of SF were different
according to the presence of NASH. Indeed, hepatocel-
lular ballooning and inﬂammation, as well as fasting
hyperglycemia and aging, were associated with SF
irrespective of the presence of NASH. On the other
hand, an independent impact of steatosis grade, as well
as of male sex, and of the PNPLA3 I148M variant was
speciﬁcally observed in patients without NASH. In
keeping, prospective cohort studies showed that in
patients with severe NASH disease progression waspredicted by ballooning or inﬂammation,10,11 while in
unselected cohorts of patients with and without NASH
disease progression was predicted by steatosis
grade.12,13 This observation may be explained by the
fact that patients with NASH already have severe fat
accumulation and activation of ﬁbrogenic pathways,
masking the role of hepatic fat accumulation in trig-
gering liver disease.
The association between steatosis grade and ﬁbrosis
in patients without NASH also was replicated in a pro-
spective cohort. Here, we conﬁrmed that during follow-
up evaluation ﬁbrosis progression occurred in as much
as 50% of cases without NASH at baseline, and in 10% of
cases without baseline histologic inﬂammation. However,
in 40% of cases without baseline NASH who had ﬁbrosis
progression, this was associated with the development of
NASH during follow-up evaluation, suggesting that they
may be affected by a remitting–relapsing form of disease,
which might have led to underestimation of the disease
activity at the time of baseline histologic evaluation.
Therefore, ﬂuctuation of disease activity during the nat-
ural history of NAFLD owing to transient modiﬁcations
of environmental triggers may contribute to the frequent
presence of clinically signiﬁcant ﬁbrosis in the absence of
NASH. Heterogeneity of liver damage distribution and
sampling variability (affecting both disease activity
grading and ﬁbrosis staging), and/or interobserver
variability in histologic scoring, especially concerning the
diagnosis of ballooning, should be considered as possible
explanations.
Despite including a large series of patients, with
validation in a prospective cohort, this study had limi-
tations. These include the retrospective design, and the
consequent impossibility to have a centralised reevalu-
ation of all slides. However, histologic evaluations were
performed by expert pathologists at tertiary referral
centers, receiving regular feedback from central histo-
logic readings in randomized controlled trials, and the
concordance for staging ﬁbrosis and steatosis was
good.19 We acknowledge that the concordance for eval-
uation of inﬂammation and ballooning, which are key for
2318 Pelusi et al Clinical Gastroenterology and Hepatology Vol. 17, No. 11the diagnosis of NASH, was only moderate.19 Notwith-
standing, in the present study these histologic features
turned out to represent the most accurate SF predictors
in all subgroups, rendering it unlikely that inaccurate
staging may account for the present ﬁndings. Further-
more, this limitation was partially compensated by the
large sample size, suggesting that results reﬂect the
clinical challenges in identifying at-risk patients in
referral center. Finally, genetic data were not available in
a subgroup, and results may not be applicable to non-
European individuals.
In conclusion, in a large multicenter cohort of pa-
tients with NAFLD, we found that a third of patients
with SF did not have histological evidence of NASH.
One out of 10 patients with SF did not have any signs
of inﬂammatory activity. In addition, the dissociation
between NASH and ﬁbrosis is more marked in severely
obese individuals. Importantly, the severity of steatosis
and the PNPLA3 I148M variant predicted SF, and
steatosis predicted ﬁbrosis progression speciﬁcally in
patients without NASH. These ﬁndings suggest that a
higher than expected proportion of patients with
NAFLD may evolve toward SF, possibly owing to ﬂuc-
tuating disease activity, which is not easily captured at
a deﬁnite time point, and/or the existence of mecha-
nisms of disease progression that may be partially
different in different subgroups.
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Part of the cross-sectional liver biopsy cohort has
been described previously.1,2 Brieﬂy, a total of 1738 in-
dividuals of European descent were consecutively
enrolled from Italian and Finnish referral centers. In-
clusion criteria were a liver biopsy for suspected NASH
or severe obesity, the presence of NAFLD, and availability
of clinical data and consent. Individuals with increased
alcohol intake (men, >30 g/d; women, >20 g/d), viral
and autoimmune hepatitis, or other causes of liver dis-
ease were excluded. The study conformed to the Decla-
ration of Helsinki and was approved by the Institutional
Review Board of the Fondazione Ca’ Granda Istituto di
Ricovero e Cura a Carattere Scientiﬁco (IRCCS) of Milan.
The clinical features of the overall cross-sectional liver
biopsy cohort and after stratiﬁcation for the enrollment
criterion is presented in Supplementary Table 1.
To validate the results prospectively, we took
advantage of a previously described multicenter cohort
of 118 patients with NAFLD with serial liver biopsies
followed up at tertiary referral centers in Italy.3 Their
clinical features have been described previously in
detail.3 Brieﬂy, they were mostly middle-aged men or
postmenopausal women, overweight or obese, with a
high prevalence of metabolic alterations deﬁning
metabolic syndrome and/or altered liver enzyme levels.
The median follow-up period was 36 months (inter-
quartile range, 24–77 mo). The FPR was calculated by
taking the ratio between the difference of ﬁbrosis stage
and the time (in months) between the baseline and
follow-up biopsy, and it was treated as a continuous
variable. Forty-nine patients (41.5%) had NASH, 46
(39.0%) had steatosis plus inﬂammation, and 23
(19.5%) had simple steatosis.Histologic Evaluation
Slides were coded and read by 1 expert pathologist at
each center who was unaware of patients’ identity and
history. A minimum 15-mm length of biopsy specimen or
the presence of at least 10 complete portal tracts was
required.4 Steatosis was graded based on the percentage
of affected hepatocytes as follows: 0, 0% to 5%; 1, 6% to
32%; 2, 34% to 66%; and 3, 67% to 100%. Disease ac-
tivity was assessed according to the NAFLD Activity
Score, with systematic evaluation of hepatocellular
ballooning and lobular inﬂammation; ﬁbrosis also was
staged according to the recommendations of the NAFLD
clinical research network.5 NASH was diagnosed when
steatosis, hepatocellular ballooning, and lobular inﬂam-
mation all were present. The concordance between pa-
thologists within this cohort was very good for ﬁbrosis,
and good for steatosis with a coefﬁcient of interobserver
agreement for ﬁbrosis, steatosis grade, lobularinﬂammation, and ballooning of 0.89, 0.76, 0.60, and
0.55, respectively.6Supplementary Results
Sensitivity Analyses
The independent predictors of advanced ﬁbrosis
(stages F3–F4) in patients stratiﬁed by the presence of
NASH are shown in Supplementary Table 3. Although the
development of advanced ﬁbrosis tends to be associated
with a reduction of liver fat and disease activity, and that
the power for this analysis was limited by the relatively
low number of patients with advanced ﬁbrosis without
NASH included in the present cohort, steatosis grade
remained nearly associated with advanced ﬁbrosis in
patients without NASH, independently of confounders,
although the association was not statistically signiﬁcant
(P ¼ .068). On the other hand, the PNPLA3 I148M variant
remained associated with advanced ﬁbrosis in both pa-
tients with and without NASH independently of the his-
tologic and metabolic features of the disease.
The independent predictors of SF after the exclu-
sion of patients with cirrhosis (stages F2–F3) in those
patients stratiﬁed by the presence of NASH are shown
in Supplementary Table 4. In keeping with what we
observed in the whole cohort, steatosis grade and the
PNPLA3 I148M variant were speciﬁc independent
predictors of clinically signiﬁcant ﬁbrosis in patients
without NASH. These data are consistent with hepatic
fat and the PNPLA3 I148M variant being a driver of the
development of liver ﬁbrosis in patients without
NASH.
The independent predictors of clinically signiﬁcant
ﬁbrosis in patients without NASH stratiﬁed by the
presence of T2D are shown in Supplementary Table 5.
Steatosis grade was the strongest independent predictor
of SF in patients without T2D; SF also was associated
with the PNPLA3 I148M variant, male sex, and lobular
inﬂammation. Despite the relatively low sample size, in
patients with T2D, SF remained independently associ-
ated with steatosis grade, together with lobular inﬂam-
mation and male sex. These data conﬁrm that steatosis
grade is an independent determinant of SF in patients
without NASH irrespective of the presence of T2D.References
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Supplementary Table 1. Demographic, Anthropometric, and Clinical Features of the Cross-Sectional Liver Biopsy Cohort
(n ¼ 1738)
Overall
(n ¼ 1738)
Liver clinic
(n ¼ 958; 55.1%)
Severe obesity
(n ¼ 780; 44.9%) P value
Sex, female 860 (49.4) 299 (31.2) 561 (71.9) <.0001
Age, y 43.7  14.8 42.8  17.5 44.7  10.6 .99
BMI, kg/m2 34.6  9.0 27.8  4.0 42.9  5.7 <.0001
Obesity 1047 (60.2) 267 (27.9) 780 (100) <.0001
T2D/IFG, yes 466 (26.8) 228 (23.8) 238 (30.5) .0017
Hypertension, yes 448 (33.3) 272 (29.3) 176 (42.5) <.0001
Total cholesterol, mg/dL 191  44 195  44 185  44 <.0001
Triglyceride level, mg/dL 139  77 138  80 140  73 .55
HDL cholesterol, mg/dL 48  14 48  14 48  14 .35
ALT, IU/L 42 (24–69) 54 (34–80) 30 (19–48) <.0001
AST, IU/L 29 (21–43) 34 (24–47) 22 (17–33) <.0001
NASH, yes 571 (32.9) 422 (44.0) 149 (19.2) <.0001
Clinically signiﬁcant ﬁbrosis, stages F2–F4 389 (22.4) 287 (30.0) 102 (13.1) <.0001
Severe ﬁbrosis, stages F3–F4 174 (10.0) 137 (14.3) 37 (4.8) <.0001
PNPLA3, 148M/Ma 234 (13.8) 168 (17.7) 66 (8.8) <.0001
NOTE. Values are reported as means  SD, medians {interquartile range}, or number (%), as appropriate. Characteristics of participants were compared using a
linear regression model or a logistic regression model (as required).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HDL, high-density lipoprotein; IFG, impaired fasting glucose; NASH,
nonalcoholic steatohepatitis; T2D, type 2 diabetes.
aThe PNPLA3 I148M genotype was available in a subset of patients (n ¼ 1698).
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Supplementary Table 2. Histologic Activity in Patients Stratiﬁed by Fibrosis Stage
Fibrosis stage
Steatosis Ballooning Lobular inﬂammation
1 2 3 0 1 2 0 1 2 3
0 558 (74.9) 114 (15.3) 73 (9.8) 618 (82.9) 108 (14.5) 19 (2.6) 513 (68.9) 201 (27.0) 31 (4.2) -
1 263 (44.4) 190 (31.6) 149 (24.7) 345 (57.3) 207 (34.4) 50 (8.3) 148 (24.6) 351 (58.3) 102 (16.9) 1 (0.2)
2 56 (26.0) 75 (34.9) 84 (39.1) 88 (40.9) 86 (40.0) 41 (19.1) 24 (11.2) 98 (45.6) 83 (38.6) 10 (4.6)
3 29 (27.1) 31 (29.0) 47 (43.9) 21 (19.6) 42 (32.2) 44 (40.2) 8 (7.5) 35 (32.7) 55 (51.4) 9 (8.4)
4 32 (47.8) 20 (29.8) 15 (22.4) 4 (6.0) 38 (56.7) 25 (37.3) 7 (10.4) 30 (44.8) 26 (38.8) 4 (6.0)
Supplementary Table 3. Independent Predictors of Clinically Signiﬁcant Fibrosis (Stages F2–F4) in the Cross-Sectional LBC
Patients Stratiﬁed According to the Presence of NASH and Modality of Recruitment (Liver Clinic Vs
Severe Obesity)
Liver clinic Severe obesity
NASH No NASH NASH No NASH
Estimate SE P value Estimate SE P value Estimate SE P value Estimate SE P value
Sex, female -0.092 0.139 .49 -0.073 0.157 .064 -0.314 0.223 .16 -0.461 0.163 .004
Age, y þ0.045 0.008 1*10-8 þ0.028 0.008 .001 þ0.001 0.019 .96 þ0.020 0.015 .18
BMI, kg/m2 þ0.098 0.034 .004 -0.015 0.037 .69 -0.054 0.047 .25 þ0.054 0.024 .030
T2D/IFG, yes þ0.515 0.139 2*10-4 þ0.477 0.164 .003 þ0.356 0.222 .10 þ0.320 0.165 .053
Steatosis, grade þ0.072 0.146 .62 þ0.409 0.152 .007 þ0.147 0.255 .57 þ0.821 0.175 3*10-6
Ballooning, grade þ0.284 0.129 .028 þ1.239 0.432 .005 þ0.592 0.283 .037 þ0.523 0.232 .024
Lobular inﬂammation, grade þ0.634 0.131 1*10-6 þ0.733 0.168 1*10-5 þ0.751 0.220 7*10-4 þ0.743 0.232 .001
PNPLA3, I148M allelesa þ0.078 0.163 .65 þ0.437 0.196 .026 þ0.359 0.183 .038 þ0.497 0.239 .024
NOTE. Characteristics of participants were compared using linear regression models.
BMI, body mass index; IFG, impaired fasting glucose; LBC, liver biopsy cohort; NASH, nonalcoholic steatohepatitis; T2D, type 2 diabetes.
aThe PNPLA3 I148M genotype was available in a subset of patients (n ¼ 1698).
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Supplementary Table 4. Independent Predictors of Advanced Fibrosis (Stages F3–F4) in the Cross-Sectional LBC Patients
Stratiﬁed According to the Presence of NASH
NASH No NASH
Estimate SE P value Estimate SE P value
Sex, female -0.142 0.118 .23 -0.350 0.214 .10
Age, y þ0.055 0.008 3*10-10 þ0.033 0.014 .022
BMI, kg/m2 -0.037 0.018 .037 -0.025 0.022 .27
T2D/IFG, yes þ0.440 0.120 2*10-4 þ0.584 0.207 .005
Steatosis, grade þ0.150 0.134 .27 þ0.395 0.217 .068
Ballooning, grade þ0.414 0.121 .007 þ1.224 0.242 4*10-7
Lobular inﬂammation, grade þ0.465 0.121 1*10-4 þ1.098 0.249 1*10-5
PNPLA3, I148M allelesa þ0.333 0.160 .037 þ0.563 0.280 .045
NOTE. Characteristics of participants were compared using linear regression models.
BMI, body mass index; IFG, impaired fasting glucose; LBC, liver biopsy cohort; NASH, nonalcoholic steatohepatitis; T2D, type 2 diabetes.
aThe PNPLA3 I148M genotype was available in a subset of patients (n ¼ 1698).
Supplementary Table 5. Independent Predictors of Clinically Signiﬁcant Fibrosis After Exclusion of Patients With Cirrhosis
(Stages F2–F3) in Patients Stratiﬁed by the Presence of NASH
NASH No NASH
Estimate SE P value Estimate SE P value
Sex, female -0.144 0.113 .20 -0.362 0.116 .002
Age, y þ0.038 0.007 8*10-8 þ0.023 0.007 .002
BMI, kg/m2 -0.022 0.015 .15 þ0.005 0.012 .67
T2D/IFG, yes þ0.275 0.115 .017 þ0.374 0.116 .001
Steatosis, grade þ0.147 0.129 .25 þ0.569 0.114 6*10-7
Ballooning, grade þ0.389 0.116 8*10-4 þ1.117 0.481 .02
Lobular inﬂammation, grade þ0.697 0.110 2*10-10 þ0.787 0.133 4*10-9
PNPLA3, I148M allelesa þ0.101 0.143 .49 þ0.432 0.153 .005
NOTE. Characteristics of participants were compared using linear regression models.
BMI, body mass index; IFG, impaired fasting glucose; NASH, nonalcoholic steatohepatitis; T2D, type 2 diabetes.
aThe PNPLA3 I148M genotype was available in a subset of patients (n ¼ 1633).
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Supplementary Table 6. Independent Predictors of Clinically Signiﬁcant Fibrosis in Patients Without NASH Stratiﬁed by the
Presence of Type 2 Diabetes
T2D (n ¼ 254) No T2D (n ¼ 911)
Estimate SE P value Estimate SE P value
Sex, female -0.188 0.183 .003 -0.412 0.145 .005
Age, y þ0.011 0.018 .32 þ0.036 0.010 3*10-4
BMI, kg/m2 þ0.002 0.019 .91 þ0.011 0.015 .47
Steatosis, grade þ0.419 0.190 .026 þ0.667 0.137 1*10-6
Ballooning, grade NA NA NA þ1.379 0.444 .002
Lobular inﬂammation, grade þ0.908 0.233 1*10-4 þ0.697 0.163 2*10-5
PNPLA3, I148M allelesa þ0.354 0.254 .16 þ0.519 0.185 .005
NOTE. Characteristics of participants were compared using linear regression models.
BMI, body mass index; NASH, nonalcoholic steatohepatitis; T2D, type 2 diabetes.
aThe PNPLA3 I148M genotype was available in a subset of patients (n ¼ 1131).
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